| Rx0000385 |
Sagent Pharmaceuticals |
06/30/2022 |
25021011482 |
Ciprofloxacin/Dextrose 5% (2mg/ml, 100ml, 24x100ml) |
04/28/2022 |
22.06 |
72.00 |
None |
Non-innovator Multiple Source Drug |
1000 |
None |
Sagent does not have sales to report as this is a re-launch |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The WAC price was lowered in December 2010 to $49.94. Due to increased competition and pricing pressures, we had to discontinue sales for this product in January 2012.
Ten years after that sales discontinuation, we have decided to bring this product back to market, and re-launched this product in May 2022. The WAC price is $72. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649041112 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 12 |
01/01/2022 |
53.63 |
732.52 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649041124 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 24 |
01/01/2022 |
107.27 |
1465.08 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649040130 |
ANUSOl-HC® (Hydrocortisone Cream, USP) 2.5%, 30gm |
01/01/2022 |
12.05 |
164.52 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649024141 |
AZASAN® (Azathioprine Tablets, USP) 100mg, 100ct |
01/01/2022 |
67.55 |
922.59 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649023141 |
AZASAN® (Azathioprine Tablets, USP) 75mg, 100ct |
01/01/2022 |
151.51 |
2069.39 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649020175 |
MOVIPREP® (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate & Ascorbic Acid for Oral Solution), 1 Kit |
01/01/2022 |
7.12 |
125.88 |
09/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649070141 |
OSMOPREP® (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) 1.5g Tablets, 100 |
01/01/2022 |
60.98 |
832.81 |
06/22/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649040001 |
PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), Kit |
01/01/2022 |
7.41 |
131.01 |
09/10/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649055102 |
RELISTOR® (methylnaltrexone bromide) 12mg/0.6mL, vial |
01/01/2022 |
10.62 |
145.14 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649055103 |
RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, 7ct |
01/01/2022 |
74.39 |
1015.98 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649055107 |
RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, vial |
01/01/2022 |
10.62 |
145.14 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649055204 |
RELISTOR® (methylnaltrexone bromide) PFS 8 mg/0.4mL, 7ct |
01/01/2022 |
74.39 |
1015.98 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649015090 |
RELISTOR® (methylnaltrexone bromide) Tablets 150mg, 90ct |
01/01/2022 |
159.40 |
2177.15 |
03/10/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649000330 |
Trulance® (plecanatide) 3mg Tablets, 30 |
01/01/2022 |
37.21 |
508.18 |
06/05/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Synergy Pharmaceuticals Inc. |
None |
1 |
Bausch Health acquired certain assets of Synergy Pharmaceuticals Inc. including Trulance in a transaction valued at approximately $200 million plus certain assumed liabilities. https://ir.bauschhealth.com/news-releases/2018/12-12-2018-113003808 |
411.78 |
388.47 |
2017 |
353.48 |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
70194000330 |
Trulance® (plecanatide) 3mg Tablets, Blister Pack of 30 |
01/01/2022 |
37.21 |
508.18 |
06/05/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Synergy Pharmaceuticals Inc. |
None |
1 |
Bausch Health acquired certain assets of Synergy Pharmaceuticals Inc. including Trulance in a transaction valued at approximately $200 million plus certain assumed liabilities. https://ir.bauschhealth.com/news-releases/2018/12-12-2018-113003809 |
411.78 |
388.47 |
2017 |
353.48 |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649065103 |
UCERIS® (budesonide) Rectal Aerosol, Foam, two 54 ml Canisters, 2 mg/actuation |
01/01/2022 |
55.71 |
760.80 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649030303 |
XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card |
01/01/2022 |
217.84 |
2975.32 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2022 |
65649030302 |
XIFAXAN® (rifaximin) 550mg Tablets, 60ct |
01/01/2022 |
217.84 |
2975.32 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000011 |
Sanofi |
03/31/2022 |
58468021002 |
AUBAGIO (teriflunomide) 14 mg tablet - blister pack of 28 |
01/03/2022 |
428.75 |
7950.68 |
09/14/2030 |
Single Source Drug |
None |
1 |
While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system.
Sanofi’s commitment to pricing rests on three principles:
CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine
LIMITED U.S. PRICE INCREASES on our medicines over time
CONTINUED TRANSPARENCY IN THE U.S. around our pricing decisions
When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.
We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year. Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year. |
None |
See Column 10 Cost Increase Factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
03/31/2022 |
58468021004 |
AUBAGIO (teriflunomide) 14 mg tablet - bottle of 30 |
01/03/2022 |
459.38 |
8518.60 |
09/14/2030 |
Single Source Drug |
None |
1 |
While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system.
Sanofi’s commitment to pricing rests on three principles:
CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine
LIMITED U.S. PRICE INCREASES on our medicines over time
CONTINUED TRANSPARENCY IN THE U.S. around our pricing decisions
When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.
We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year. Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year. |
None |
See Column 10 Cost Increase Factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
03/31/2022 |
58468021101 |
AUBAGIO (teriflunomide) 7 mg tablet - blister pack of 28 |
01/03/2022 |
427.75 |
7950.68 |
09/14/2030 |
Single Source Drug |
None |
1 |
While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system.
Sanofi’s commitment to pricing rests on three principles:
CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine
LIMITED U.S. PRICE INCREASES on our medicines over time
CONTINUED TRANSPARENCY IN THE U.S. around our pricing decisions
When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.
We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year. Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year. |
None |
See Column 10 Cost Increase Factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
03/31/2022 |
58468021104 |
AUBAGIO (teriflunomide) 7 mg tablet - bottle of 30 |
01/03/2022 |
459.38 |
8518.60 |
09/14/2030 |
Single Source Drug |
None |
1 |
While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system.
Sanofi’s commitment to pricing rests on three principles:
CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine
LIMITED U.S. PRICE INCREASES on our medicines over time
CONTINUED TRANSPARENCY IN THE U.S. around our pricing decisions
When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.
We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year. Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year. |
None |
See Column 10 Cost Increase Factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
09/30/2022 |
00024515010 |
Elitek (rasburicase) 1.5 mg/ml 3 vials + 3 ampules |
07/01/2022 |
80.47 |
3037.91 |
None |
Single Source Drug |
None |
1 |
In 2017, Sanofi announced our progressive and industry-leading pricing principles to help stakeholders understand our pricing decisions and to advance a more informed discussion of issues related to the pricing of medicines. These principles include a pledge to keep annual list price increases at or below the projected U.S. National Health Expenditure (NHE) growth rate, an estimate of medical spending calculated by the Centers for Medicare and Medicaid Services (CMS) and often used as a measure of healthcare inflation. These principles apply to all of our prescription medicines if a pricing decision results in more than a $15 annual increase in the price of the medication. In addition, we committed to making both our average aggregate list and net price changes across our portfolio transparent to help illustrate how revenue accrues to Sanofi versus other parts of the pharmaceutical supply chain. For more information on our pricing principles, please download our 2022 report: https://www.sanofi.us/en/corporate-responsibility/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
09/30/2022 |
00024515175 |
Elitek (rasburicase) 7.5 mg/ml 1 vial + 1 ampule |
07/01/2022 |
134.13 |
5063.18 |
None |
Single Source Drug |
None |
1 |
In 2017, Sanofi announced our progressive and industry-leading pricing principles to help stakeholders understand our pricing decisions and to advance a more informed discussion of issues related to the pricing of medicines. These principles include a pledge to keep annual list price increases at or below the projected U.S. National Health Expenditure (NHE) growth rate, an estimate of medical spending calculated by the Centers for Medicare and Medicaid Services (CMS) and often used as a measure of healthcare inflation. These principles apply to all of our prescription medicines if a pricing decision results in more than a $15 annual increase in the price of the medication. In addition, we committed to making both our average aggregate list and net price changes across our portfolio transparent to help illustrate how revenue accrues to Sanofi versus other parts of the pharmaceutical supply chain. For more information on our pricing principles, please download our 2022 report: https://www.sanofi.us/en/corporate-responsibility/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
09/30/2022 |
00024582411 |
Jevtana (cabazitaxel) 60 mg vial 1.5 ml carton |
07/01/2022 |
291.01 |
12816.67 |
None |
Single Source Drug |
None |
1 |
In 2017, Sanofi announced our progressive and industry-leading pricing principles to help stakeholders understand our pricing decisions and to advance a more informed discussion of issues related to the pricing of medicines. These principles include a pledge to keep annual list price increases at or below the projected U.S. National Health Expenditure (NHE) growth rate, an estimate of medical spending calculated by the Centers for Medicare and Medicaid Services (CMS) and often used as a measure of healthcare inflation. These principles apply to all of our prescription medicines if a pricing decision results in more than a $15 annual increase in the price of the medication. In addition, we committed to making both our average aggregate list and net price changes across our portfolio transparent to help illustrate how revenue accrues to Sanofi versus other parts of the pharmaceutical supply chain. For more information on our pricing principles, please download our 2022 report: https://www.sanofi.us/en/corporate-responsibility/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
03/31/2022 |
00024592001 |
KEVZARA (sarilumab) 150 mg/1.14 mL pen - carton of 2 pens |
01/03/2022 |
208.44 |
3865.35 |
12/06/2031 |
Single Source Drug |
None |
1 |
While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system.
Sanofi’s commitment to pricing rests on three principles:
CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine
LIMITED U.S. PRICE INCREASES on our medicines over time
CONTINUED TRANSPARENCY IN THE U.S. around our pricing decisions
When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.
We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year. Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year. |
None |
See Column 10 Cost Increase Factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
03/31/2022 |
00024590801 |
KEVZARA (sarilumab) 150 mg/1.14 mL syringe - carton of 2 syringes |
01/03/2022 |
208.44 |
3865.35 |
12/06/2031 |
Single Source Drug |
None |
1 |
While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system.
Sanofi’s commitment to pricing rests on three principles:
• CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine
• LIMITED U.S. PRICE INCREASES on our medicines over time
• CONTINUED TRANSPARENCY IN THE U.S. around our pricing decisions
When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.
We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year. Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year. |
None |
See Column 10 Cost Increase Factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
03/31/2022 |
00024592201 |
KEVZARA (sarilumab) 200 mg/1.14 mL pen - carton of 2 pens |
01/03/2022 |
208.44 |
3865.35 |
12/06/2031 |
Single Source Drug |
None |
1 |
While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system.
Sanofi’s commitment to pricing rests on three principles:
CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine
LIMITED U.S. PRICE INCREASES on our medicines over time
CONTINUED TRANSPARENCY IN THE U.S. around our pricing decisions
When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.
We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year. Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year. |
None |
See Column 10 Cost Increase Factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
03/31/2022 |
00024591001 |
KEVZARA (sarilumab) 200 mg/1.14 mL syringe - carton of 2 syringes |
01/03/2022 |
208.44 |
3865.35 |
12/06/2031 |
Single Source Drug |
None |
1 |
While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system.
Sanofi’s commitment to pricing rests on three principles:
• CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine
• LIMITED U.S. PRICE INCREASES on our medicines over time
• CONTINUED TRANSPARENCY IN THE U.S. around our pricing decisions
When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.
We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year. Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year. |
None |
See Column 10 Cost Increase Factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000092 |
Santarus, Inc. |
03/31/2022 |
68012025820 |
CYCLOSET® (bromocriptine mesytate tablets) 0.8 mg tablets, 200 ct |
01/01/2022 |
75.78 |
1035.08 |
04/30/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2022 |
70257053251 |
Cytomegalovirus Immune Globulin Intravenous (Human), 1 single dose vial (50 mL) |
01/03/2022 |
131.85 |
1613.27 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/06/2019 |
CSL Behring |
None |
1 |
None |
1285.00 |
1285.00 |
1998 |
1164.00 |
None |
We do not have the WAC at Intro to Market for CytoGam. MedImmune was the company that first marketed the product. 2011 price of $1,164.00 is the oldest price we have. |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2022 |
70257012651 |
VARIZIG, single dose vial of 125 IU in 1.2mL |
01/03/2022 |
111.66 |
2004.20 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/27/2017 |
Aptevo Therapeutics |
None |
1 |
None |
1306.34 |
1185.00 |
2012 |
682.50 |
None |
Varizig introduced to the market in 2012 as lyophilized powder. Current formulation is liquid.
Patent Exp. Date: N/A (Biologic status) |
| Rx0000086 |
Seagen, Inc. |
12/31/2022 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
12/29/2022 |
392.00 |
10470.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Healthcare Access and Information ("HCAI") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product. |
| Rx0000086 |
Seagen, Inc. |
09/30/2022 |
51144002001 |
PADCEV (enfortumab vedotin-ejfv) 20 mg lyophilized powder in a single-dose vial for reconstitution |
09/29/2022 |
95.00 |
2552.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000086 |
Seagen, Inc. |
09/30/2022 |
51144003001 |
PADCEV (enfortumab vedotin-ejfv) 30 mg lyophilized powder in a single-dose vial for reconstitution |
09/29/2022 |
142.50 |
3828.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000086 |
Seagen, Inc. |
12/31/2022 |
51144000212 |
TUKYSA, 150mg, 120 Count Oral Tablet per Bottle |
12/29/2022 |
1938.00 |
23514.00 |
04/27/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) The patent expiration date listed reflects the latest expiring of certain granted patents that currently cover TUKYSA. Additional patents may be granted from existing and future patent applications and may have different expiry dates. The expiry date listed is based on current assumptions and existing information; patent expiry dates are subject to change. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product. |
| Rx0000086 |
Seagen, Inc. |
12/31/2022 |
51144000260 |
TUKYSA, 150mg, 60 Count Oral Tablet per Bottle |
12/29/2022 |
969.00 |
11757.00 |
04/27/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) The patent expiration date listed reflects the latest expiring of certain granted patents that currently cover TUKYSA. Additional patents may be granted from existing and future patent applications and may have different expiry dates. The expiry date listed is based on current assumptions and existing information; patent expiry dates are subject to change. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product. |
| Rx0000086 |
Seagen, Inc. |
12/31/2022 |
51144000160 |
TUKYSA, 50mg, 60 Count Oral Tablet per Bottle |
12/29/2022 |
482.00 |
5847.00 |
04/27/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) The patent expiration date listed reflects the latest expiring of certain granted patents that currently cover TUKYSA. Additional patents may be granted from existing and future patent applications and may have different expiry dates. The expiry date listed is based on current assumptions and existing information; patent expiry dates are subject to change. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product. |
| Rx0000086 |
Seattle Genetics, Inc. |
06/30/2022 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
06/30/2022 |
378.00 |
10078.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Healthcare Access and Information ("HCAI") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product. |
| Rx0000086 |
Seattle Genetics, Inc. |
03/31/2022 |
51144002001 |
PADCEV (enfortumab vedotin-ejfv) 20 mg lyophilized powder in a single-dose vial for reconstitution |
03/31/2022 |
92.00 |
2457.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000086 |
Seattle Genetics, Inc. |
03/31/2022 |
51144003001 |
PADCEV (enfortumab vedotin-ejfv) 30 mg lyophilized powder in a single-dose vial for reconstitution |
03/31/2022 |
138.00 |
3685.50 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2022 |
71779011502 |
Copiktra 15 mg 56-count capsules |
04/04/2022 |
1628.16 |
18074.31 |
01/10/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2022 |
71779011502 |
Copiktra 15 mg oral capsule, 56 caps per package |
11/14/2022 |
5949.45 |
24020.76 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
70000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2022 |
71779012502 |
Copiktra 25 mg 56-count capsules |
04/04/2022 |
1628.16 |
18074.31 |
01/10/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2022 |
71779012502 |
Copiktra 25 mg oral capsule, 56 caps per package |
11/14/2022 |
5949.45 |
24020.76 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
70000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2022 |
73116022556 |
Copiktra 25 mg oral capsule, 56 caps per package. Secura Bio labeler code |
11/14/2022 |
5949.45 |
24020.76 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
70000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000028 |
Servier Pharmaceuticals LLC |
03/31/2022 |
72694095401 |
Oncaspar Injection Solution 750 Unit/ML, 5 ML, Unit-Dose, Vial |
01/01/2022 |
1901.85 |
22242.46 |
None |
Single Source Drug |
None |
1 |
The increase of wholesale Acquisition Cost (WAC) for the product is due to increases in many factors that could include the cost of manufacturing and distribution, increases in the cost of ingredients, increases in shipping for the product and increases in the costs to market the product. There are many other non-financial factors that have impacted the decision including COVID-19, company structure, market access and others. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000376 |
Stemline Therapeutics |
09/30/2022 |
72187040101 |
ELZONRIS 1,000mcg/mL, VIAL (ML), 1 |
07/15/2022 |
5.00 |
30912.68 |
06/29/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Stemline considers many factors in determining the price of its product, ELZONRIS, including Stemline’s post-marketing regulatory obligations associated with the product, ongoing pharmacovigilance, costs associated with the cold chain distribution process, and market conditions and dynamics. Recently, increasing rates of inflation have been a significant consideration for Stemline. (2) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Stemline believes is otherwise in the public domain or publicly available. Where possible, Stemline has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(3) For Columns 14-22, Stemline has not provided a response as the compound was acquired from an unrelated company more than 5 years ago. |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2022 |
27505000401 |
Apokyn Subcutaneous Solution Cartridge 30 MG/3ML |
07/01/2022 |
86.43 |
1321.10 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2022 |
27505000405 |
Apokyn Subcutaneous Solution Cartridge 30 MG/3ML Cartridge Qty 5 |
07/01/2022 |
432.14 |
6605.51 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2022 |
17772012101 |
Oxtellar XR 150mg X 100, capsule |
01/01/2022 |
45.49 |
803.59 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2022 |
17772012201 |
Oxtellar XR 300mg X 100, capsule |
01/01/2022 |
63.19 |
1116.40 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2022 |
17772012301 |
Oxtellar XR 600mg X 100, capsule |
01/01/2022 |
115.70 |
2044.02 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2022 |
17772010330 |
Trokendi XR 100mg X 30, capsule |
01/01/2022 |
50.84 |
898.16 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2022 |
17772010301 |
Trokendi XR 100mg X100, capsule |
01/01/2022 |
169.47 |
2993.89 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2022 |
17772010430 |
Trokendi XR 200mg X 30, capsule |
01/01/2022 |
69.55 |
1228.64 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2022 |
17772010401 |
Trokendi XR 200mg X100, capsule |
01/01/2022 |
231.82 |
4095.42 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2022 |
17772010130 |
Trokendi XR 25mg X 30, capsule |
01/01/2022 |
19.70 |
348.01 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2022 |
17772010101 |
Trokendi XR 25mg X100, capsule |
01/01/2022 |
65.66 |
1160.04 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2022 |
17772010230 |
Trokendi XR 50mg X 30, capsule |
01/01/2022 |
25.66 |
453.31 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2022 |
17772010201 |
Trokendi XR 50mg X100, capsule |
01/01/2022 |
85.53 |
1511.07 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2022 |
27505011130 |
Xadago Oral Tablet 100 MG |
07/01/2022 |
78.15 |
1055.08 |
03/21/2031 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2022 |
27505011030 |
Xadago Oral Tablet 50 MG |
07/01/2022 |
78.15 |
1055.08 |
03/21/2031 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |